Daniel Finley is a Professor of Cell Biology at Harvard Medical School (HMS), leading the Finley Lab focused on the ubiquitin-proteasome pathway and related regulatory mechanisms. He holds academic appointments within the Department of Cell Biology and sits on the Scientific Advisory Boards of Proteostasis and X-Chem Pharmaceuticals. His research investigates proteasome function, ubiquitin-like proteins, and proteostasis roles in diseases like Alzheimer’s and ALS. Dr. Finley earned his undergraduate degree in biochemistry from Harvard University and a Ph.D. in molecular biology from MIT. After postdoctoral training at MIT, he joined HMS in 1988. His lab explores topics including erythroid proteome remodeling, mitochondrial dysfunction, and neurodegenerative disease mechanisms. Key research areas include: (1) Ubiquitin-proteasome pathway regulation, (2) Proteasome structure/function, (3) Nonproteolytic roles of ubiquitination, and (4) Pathophysiological roles of proteostasis defects in diseases. His work bridges basic cell biology with translational medicine, particularly in neurodegeneration and anemia. Finley has secured NIH funding for projects like 'Regulation of Proteasome Activity' (R35GM145246) and 'Erythrocyte maturation through global proteome remodeling' (R01HL153970). Collaborations with industry and academic partners extend his impact in drug discovery and proteasome-targeted therapies. His lab’s contributions include defining ubiquitin chain editing mechanisms, identifying USP14’s role in mitophagy, and elucidating proteostasis defects in Alzheimer's models. Research tools developed include advanced cryo-EM analyses of proteasomal structures and functional assays for ubiquitin system enzymes.
James B. Kaper is a Professor and Chair of the Department of Microbiology & Immunology at the University of Maryland School of Medicine. He serves as Vice Dean for Academic Affairs and previously held leadership roles as Senior Associate Dean (2014–2019) and Chair (2007–present). His research focuses on the molecular pathogenesis of diarrheagenic Escherichia coli and Vibrio cholerae , including vaccine development and bacterial-host interactions. Education: BS (1973) and PhD (1979) in Microbiology from University of Maryland; Postdoc in Molecular Pathogenesis at University of Washington (1979–1981) Dr. Kaper’s work has led to the creation of live attenuated cholera vaccines, including CVD 103-HgR, the first licensed recombinant bacterial vaccine. His lab investigates bacterial genetics, intestinal colonization, and immune system activation, particularly TLR5 response to V. cholerae flagellin. He has authored 303 peer-reviewed articles and 68 book chapters. His research has been funded continuously by NIAID since 1982. Key publications include foundational work on V. cholerae vaccines (1984), genomic structure (1998), and quorum sensing in EHEC/EPEC (1999). His lab’s recent studies focus on phosphotyrosine proteomics (2013) and pathogenicity island regulation (2007). Scientific awards: Fellow, American Academy of Microbiology (1994); NIH Merit Award (2004); ASM DC White Award (2019) Editorial roles: Editor-in-Chief, EcoSal (2006–present); Associate Editor, International Journal of Medical Microbiology (2000–present) As an academic leader, Dr. Kaper has mentored over 60 graduate students and postdoctoral fellows. He holds multiple patents for cholera vaccines and E. coli diagnostics, including U.S. Patents 4,935,364; 5,399,494; and 6,204,004. His lab at UMSOM combines basic science with translational applications for enteric disease prevention.
Dr. Giulia Biancon is an Assistant Professor Adjunct in the Department of Medical Oncology and Hematology at Yale School of Medicine. She holds a PhD from the University of Milan (2019) and is a member of the Halene Lab, focusing on RNA biology and hematologic malignancies. Her research combines high-throughput methodologies to study RNA mechanisms in diseases like myeloid leukemias and splicing factor mutations. Education: PhD in Molecular Biology from the University of Milan (2019). Research Interests: RNA splicing, stress granules in cancer, epitranscriptomics, clonal hematopoiesis, and the interplay between genetic mutations and cellular pathways in blood cancers. Awards: 2024 Eclipse Award, 2022 ASH Abstract Achievement Award, and 2022 RNA Society Best Poster Award. Her work has been published in journals like Cell Reports , Blood , and Molecular Cell . Labs/Teams: Principal member of the Halene Lab and coordinator at the Yale Center for RNA Science and Medicine. Collaborates with institutions like the SeroNet network for immunology studies.
James Briscoe is a Senior Group Leader at The Francis Crick Institute in London, where he leads a research group focused on developmental biology and morphogen signaling. He previously held positions at the Medical Research Council's National Institute for Medical Research, which later became part of the Francis Crick Institute. Education: BSc in Microbiology and Virology from the University of Warwick, UK PhD from Imperial Cancer Research Fund/King's College London Postdoctoral training at Columbia University with Thomas Jessell Dr. Briscoe's research focuses on the molecular and cellular mechanisms of graded signaling by morphogens and the role of transcriptional networks in cell fate specification. His laboratory employs a range of experimental and computational techniques using model systems including mouse and chick embryos and embryonic stem cells. His work has significant implications for understanding developmental processes and their relationship to disease. His recent publications demonstrate a continued focus on morphogen gradients, neural tube development, and computational approaches to understanding cell fate decisions. His research increasingly integrates single-cell technologies and computational modeling to unravel the complexities of developmental patterning. Scientific Awards and Honors: EMBO Young Investigator (2001) EMBO Gold Medal (2008) Elected to EMBO (2009) Fellow of the Academy of Medical Sciences (2019) Fellow of the Royal Society (2019) As Editor-in-Chief of the journal Development since 2018, Dr. Briscoe plays a significant role in shaping the field of developmental biology. His leadership extends to mentoring researchers and contributing to scientific policy discussions, as evidenced by his recent publication 'Science under siege: protecting scientific progress in turbulent times.' Dr. Briscoe's laboratory at the Crick Institute is well-equipped with access to advanced facilities including light microscopy, flow cytometry, genomics, and computational resources, enabling a multidisciplinary approach to developmental biology questions.
Kristian Helin is Chief Executive and President of The Institute of Cancer Research (ICR), London, and a Professor with affiliations at the University of Copenhagen and Memorial Sloan Kettering Cancer Center. He founded/directed the Biotech Research & Innovation Centre (BRIC), Centre for Epigenetics, and Danish Stem Cell Center. His research focuses on epigenetic regulation, cancer biology, and stem cell differentiation. Education: Ph.D. Molecular Biology, University of Copenhagen (1991) M.Sc. Chemical Engineering, Technical University of Denmark (1988) Research Interests: Helin's work deciphers molecular mechanisms in cancer, emphasizing epigenetic drivers (e.g., H3K4/H3K36 methylation), transcriptional control, and therapeutic targeting. His lab identified E2F transcription factors, linked epigenetic dysregulation to leukemia/lymphoma, and develops drugs targeting kinases/epigenetic enzymes. Research spans acute myeloid leukemia, B-cell lymphoma, and solid tumors using CRISPR screens and preclinical models. Publication Trends: Recent articles (2023-2025) focus on epigenetic therapy, chromatin remodeling, and kinase signaling in cancer. Key themes include targeting NSD1/KDM5C/RIOK2 enzymes, combination therapies (EZH2/DOT1L inhibitors), and metabolic regulation in leukemia. Studies bridge basic mechanisms (enhancer regulation, insulator accessibility) with translational applications. Awards: Anders Jahre Prize (2014), ERC Advanced Grant (2011), Novo Nordisk Prize (2008) Memberships: Academia Europaea, Royal Danish Academy, EMBO Leadership: Helin co-founded EpiTherapeutics (acquired by Gilead) and leads the Epigenetics and Cancer lab at ICR. His team investigates AML pathogenesis and chromatin complexes like HUSH/NURF. Grants include ERC funding and innovation prizes.
Marie Sandberg is an Associate Professor in the Promotion Programme at the Saxo Institute, University of Copenhagen. She is affiliated with the Faculty of Humanities and participates in HUM:Global initiatives focused on interdisciplinary global studies. Her research emphasizes ethnological analyses of migration, borders, and refugee policies, particularly exploring temporal governance, state-civil society interactions, and the paradoxes of welfare-state frameworks. Her work examines the everyday practices of refugees and volunteers in contexts of temporary protection status, as well as the ethical challenges in digital migration studies. She contributes to debates on deterrence policies, repatriation agendas, and the precarity of academic labor. Sandberg’s research methodologies often combine ethnography with critical analysis of policy frameworks. Key Research Themes: Refugee temporariness, border studies, humanitarianism, and academic precarity Professional Roles: Member of the Professional Project Group (PPG) in HUM:Global, coordinating interdisciplinary projects Geographic Focus: Europe, with emphasis on Denmark, Poland, and Germany Recent publications highlight her focus on the interplay between state policies and grassroots efforts, as well as the temporal dimensions of displacement. She has co-edited special issues on migration and authored studies on volunteerism in refugee relief work.
Dr. Vakil Takhaveev is a Lecturer at ETH Zurich's Department of Health Sciences and Technology, within the Institute of Food, Nutrition and Health. His research focuses on DNA damage mechanisms, aging, cancer, and neurodegeneration, with particular emphasis on developing novel DNA-damage-sequencing methods like click-code-seq and TRABI-Seq . He investigates anticancer drug action (e.g., trabectedin), aging clocks using DNA oxidation profiling, and stress-induced carcinogenesis. His work integrates multi-omics approaches and advanced sequencing techniques. Research Directions: Novel DNA-Damage-Sequencing Methods: Developed click-code-seq and TRABI-Seq for genomic mapping of DNA lesions and repair dynamics. Anticancer Drug Action: Explored mechanisms of trabectedin and other chemotherapeutics, linking DNA repair vulnerabilities to therapy resistance. Aging Clocks: Created DNA oxidation-based biomarkers for biological aging using genome-wide profiling in human and mouse models. Stress-Induced Pathologies: Studies metabolic and DNA damage links to early tumorigenesis and neurodegeneration. Awards & Recognition: 2025 Public Award Winner in PIs of Tomorrow competition 2024 ETH Zurich Career Seed Award Best presentation awards (Swiss Chemical Society, American Chemical Society) Grants & Collaborations: Impetus grants for aging clock development Swiss Chemical Society and American Chemical Society fellowships Labs & Teams: Leads research on DNA damage and aging mechanisms at ETH Zurich, collaborating with international groups in oncology and toxicology.
Thibault Mayor is a Professor in the Department of Biochemistry and Molecular Biology and the Michael Smith Laboratories at the University of British Columbia (Vancouver). His research focuses on understanding how cells manage misfolded proteins, with implications for neurodegenerative diseases like Parkinson's and Alzheimer's. He holds academic affiliations with the Centre for High-Throughput Biology (CHiBi) and has been recognized with awards including the UBC Killam Teaching Award (2020). Education: BSc, University of Geneva, Switzerland (1997) PhD, University of Geneva & Max Planck Institute of Biochemistry, Germany (2001) Postdoctoral Fellow, California Institute of Technology (2002) Research Interests: Mayor's lab investigates protein homeostasis, ubiquitin-proteasome system dynamics, and the molecular mechanisms underlying protein aggregation in aging and disease. Projects include proteomic approaches to identify aggregation-prone proteins and develop microbial cell factories for protein production. Grants & Awards: CIHR Project Grant ($730K, 2018) Michael Smith Foundation Career Award (2012) UBC Killam Teaching Award (2020) Labs & Collaborations: The Mayor Lab is part of the Michael Smith Laboratories and collaborates with computational biologists like Jörg Gsponer. They maintain active partnerships in proteomics and systems biology, contributing to initiatives like the BC Proteomics Network.
Marc V Fuccillo is an Associate Professor of Neuroscience at the Perelman School of Medicine, University of Pennsylvania, where he leads a research laboratory focused on understanding the neural circuit mechanisms underlying behavioral control. His work bridges molecular, synaptic, and behavioral approaches to investigate how striatal circuits regulate mouse behavior from simple motor patterns to complex goal-directed actions. Fuccillo holds dual appointments in the Neuroscience and Cell and Molecular Biology Graduate Groups at Penn and maintains an active laboratory investigating the synaptic and circuit basis of neuropsychiatric disorders. Education: B.A. in Molecular and Cellular Biology and Music Performance (Violin) from Brown University (1998) Ph.D. in Developmental Genetics from New York University School of Medicine (2007) M.D. from New York University School of Medicine (2008) Fuccillo's research centers on the synaptic and circuit mechanisms of behavioral control, with particular emphasis on striatal circuits. His laboratory employs a range of technologies including mouse genetics, in vitro electrophysiology, in vivo imaging, and quantitative behavioral analysis to explore how neural circuits of the striatum regulate behavior and how disruptions in these circuits contribute to neuropsychiatric disorders. His work has particularly focused on autism-associated abnormalities in behavioral control, examining how synaptic adhesion molecules like neuroligins and neurexins shape circuit function and behavior, with significant findings regarding D1 dopamine receptor positive medium spiny neurons in the nucleus accumbens. Analysis of Fuccillo's recent publications reveals a strong focus on striatal circuit function across multiple dimensions. His work spans molecular neuroscience (examining synaptic adhesion molecules), cellular physiology (studying specific neuron types in striatal circuits), systems neuroscience (mapping circuit connectivity), and behavioral neuroscience (quantifying motor learning and decision-making). A unifying theme is how disruptions in specific molecular pathways lead to circuit-level abnormalities that manifest as behavioral phenotypes relevant to neuropsychiatric disorders, with particular attention to autism, OCD, and schizophrenia models. Scientific Recognition: Publications in high-impact journals including Nature Neuroscience, Current Biology, Cell Reports, and Neuron Research supported by multiple NIH grants including NIMH F32, NIMH K01, and HHMI Gilliam Fellowship awards for lab members Fuccillo actively mentors a diverse group of trainees including postdoctoral fellows, graduate students, and undergraduates. His laboratory has produced numerous successful alumni who have gone on to faculty positions, medical residencies, and graduate programs at prestigious institutions. His mentoring approach emphasizes technical skill development across multiple neuroscience disciplines while fostering independent scientific thinking. Current research in his lab is supported by NIH funding focused on understanding the molecular architecture of striatal circuits and their role in behavioral control, with three major research directions exploring molecular logic of striatal circuits, circuit mechanisms of behavioral control, and striatal dysfunction in neuropsychiatric disease models. The Fuccillo Laboratory operates within the Department of Neuroscience at the University of Pennsylvania, with access to state-of-the-art facilities for molecular, electrophysiological, imaging, and behavioral neuroscience research. The lab maintains active collaborations with other neuroscience research groups at Penn and beyond, creating a rich intellectual environment for studying the neural basis of behavior. Current research directions include investigating whether there is a molecular logic to striatal circuit composition, how striatal circuits shape behavioral control, and what mouse models of autism, schizophrenia, and OCD can reveal about striatal circuit dysfunction in disease pathophysiology.
David S. Eisenberg is a Professor of Chemistry and Biochemistry and Biological Chemistry at the University of California, Los Angeles, where he also serves as Director of the UCLA-DOE Institute for Genomics and Proteomics and as an HHMI Investigator. His research focuses on protein interactions, particularly the structural basis for conversion of normal proteins to the amyloid state and conversion of prions to the infectious state. Dr. Eisenberg earned his undergraduate degree in biochemical sciences from Harvard College and his D.Phil. degree in theoretical chemistry from Oxford University on a Rhodes Scholarship. His postdoctoral research was on ice and water with Walter Kauzmann at Princeton and in protein crystallography with Richard Dickerson. He joined the UCLA faculty after his postdoctoral studies. Dr. Eisenberg and his research group focus on protein interactions in amyloid and prion diseases. These diseases involve protein aggregation where normal functional proteins convert to abnormal aggregated forms. Systemic amyloid diseases like dialysis-related amyloidosis result from fiber accumulation until organ failure, while neurodegenerative diseases like Alzheimer's, Parkinson's, ALS, and prion conditions appear to be caused by smaller oligomers. In 2005, his team determined the atomic-level structure for the amyloid fiber spine, revealing a 'steric zipper' of two parallel beta sheets packed across a dry interface. Since then, they've determined approximately 90 amyloid spines from 15 disease-related proteins. In 2010, they identified the structure of a toxic amyloid-related oligomer consisting of six anti-parallel beta strands forming a cylindrical barrel. His recent publications demonstrate continued innovation in amyloid research, with focus areas including structural prediction of amyloid formation, mechanisms of tau fibril disassembly in Alzheimer's disease, cryo-EM analysis of amyloid polymorphism, and structure-based design of inhibitors for amyloid toxicity. His work integrates computational, structural, and biochemical approaches to understand protein aggregation across multiple disease contexts. Dr. Eisenberg has received numerous prestigious awards and honors: National Academy of Sciences Member American Philosophical Society Member Institute of Medicine Member Howard Hughes Medical Institute Investigator Biophysical Society Emily M. Gray Award Harvard Westheimer Medal UCLA Seaborg Medal Technion - Israel Institute of Technology Harvey Prize in Human Health As Director of the UCLA-DOE Institute for Genomics and Proteomics and an HHMI Investigator, Dr. Eisenberg leads significant research initiatives in protein structure and aggregation. His laboratory combines X-ray crystallography, bioinformatics, and biochemical techniques to investigate protein interactions, with particular emphasis on amyloid-forming proteins and their role in disease. The Eisenberg Lab, located in Boyer Hall at UCLA, maintains an active research program investigating the structural basis of protein aggregation. The lab continues to build on its landmark discoveries of amyloid structures while exploring new frontiers in understanding protein misfolding diseases and developing potential therapeutic interventions.
David Vocadlo is a Distinguished Professor of Chemistry and Molecular Biology & Biochemistry at Simon Fraser University (SFU), holding the Canada Research Chair in Chemical Biology. His research focuses on Chemical Glycobiology, investigating carbohydrate-processing enzymes and developing chemical tools to study glycan roles in health and disease. His lab explores O-GlcNAc signaling, neurodegenerative disorders (e.g., Alzheimer’s, Parkinson’s), and enzyme inhibitors for therapeutic applications. Education: PhD from University of British Columbia (UBC), followed by a CIHR postdoctoral fellowship at UC Berkeley. Key roles include E.W.R. Steacie Memorial Fellow and Royal Society Fellow. Research highlights include O-GlcNAcase inhibitors for neuroprotection, glycan structure-function relationships, and enzyme activity imaging tools. Collaborates globally with experts in glycobiology and employs cutting-edge techniques like chemical synthesis, mass spectrometry, and live-cell imaging. Awards: Distinguished Professor title, Canada Research Chair, Royal Society Fellowship. Active in training researchers through SFU’s graduate programs, emphasizing interdisciplinary approaches. Lab members work on topics ranging from enzyme mechanisms to disease modeling.
Zhe Ji is an Assistant Professor in the Department of Biomedical Engineering at McCormick School of Engineering and the Department of Pharmacology at Feinberg School of Medicine, Northwestern University. His research integrates computational and experimental genomics to study gene transcription and RNA translation in cell fate commitment and oncogenic processes, aiming to develop precision medicine strategies. **Education**: Postdoctoral Fellow in Cancer Systems Biology, Harvard Medical School Postdoctoral Fellow in Computational Biology, Broad Institute of MIT and Harvard Ph.D. in Computational Genomics, Rutgers University B.S. in Biotechnology, Nanjing University, China **Research Focus**: Keywords include Data Science, Computational Biology, Functional Genomics, RNA, Cancer, Inflammation, and Machine Learning. The lab explores regulatory mechanisms underlying disease, with a focus on translational control, cancer metastasis, and inflammatory networks. **Grants & Advising**: No specific grants or student advisees listed. The lab emphasizes collaborative projects and computational-experimental approaches. **Lab Affiliations**: Zhe Ji’s lab is part of Northwestern’s interdisciplinary environment, bridging engineering and medicine to advance genomic technologies and therapeutic strategies.
Prof. Waldemar Kolanus leads the Molecular Immunology and Cell Biology department at the University of Bonn's Life & Medical Sciences Institute (LIMES) . His research bridges immunoregulation , stem cell dynamics , and metabolic stress responses in immune cells. Unit 2 member at LIMES Principal investigator in SFB 704 and ImmunoSensation Cluster Leads a multidisciplinary lab with postdocs, PhD students, and technical staff His work focuses on intracellular signaling pathways connecting immune activation to tissue homeostasis, particularly through: Cytohesin proteins in integrin-mediated adhesion and migration TRIM71 in stem cell regulation and congenital hydrocephalus High-salt environments affecting macrophage function Publication trends show expertise in immune cell migration , genetic models , and chemical inhibition , with frequent use of mice and zebrafish for in vivo studies. Key articles explore: TRIM71's dual role in auditory development and germ cell maintenance Cytohesin family's Golgi regulation and insulin signaling Ruxolitinib's off-target migration inhibition of dendritic cells Contact details: Address: LIMES Institute, Carl-Troll-Straße 31, Bonn Email: kolanus.sekretariat@uni-bonn.de Phone: +49 228 73-62788
Priya Raman, Ph.D., FCVS, is an Associate Professor of Integrative Medical Sciences at Northeast Ohio Medical University (NEOMED). She holds tenure and serves as Co-Director of the Basic and Translational Biomedicine (BTB) Graduate Program and Chair of the Kent State University-Biomedical Sciences Pharmacology Graduate Program. Her academic roles include teaching in NEOMED’s medical curriculum, focusing on pharmacology, cardiovascular systems, and clinical therapeutics. Raman’s research explores molecular mechanisms linking metabolic disorders (e.g., diabetes, metabolic syndrome) to vascular dysfunction and Alzheimer’s disease, using mouse models and cellular/molecular techniques. She has published extensively on thrombospondin-1, O-GlcNAc signaling, and atherosclerosis pathogenesis. Education: B.Pharm. and M.Pharm. (India), Ph.D. in Pharmacology (University of Louisiana at Monroe). She has over 25 years of postdoctoral and faculty experience, including roles at the Cleveland Clinic and Indiana University School of Medicine. Raman serves on editorial boards for journals like International Journal of Cardiology and Frontiers in Cardiovascular Medicine , and reviews grants for the American Heart Association and NIH. Research focus areas include: (1) Vascular smooth muscle cell phenotypic switching in metabolic diseases, (2) Non-lipid mechanisms of vascular disease in metabolic syndrome, and (3) Interactions between metabolic disorders and neurodegeneration. Her lab employs biochemical assays, mouse models (e.g., ApoE-/-, KKAy), and advanced imaging techniques to study these pathways. Notable recent work includes discovering that O-GlcNAc transferase deletion reduces atherosclerosis in hyperglycemic mice and identifying thrombospondin-1’s role in leptin-driven vascular pathology. She has also linked metabolic syndrome-induced O-GlcNAc deficits to Alzheimer’s-like cognitive impairment in aging mice. Raman is actively involved in interprofessional education and mentoring, directing graduate programs and teaching courses in pharmacology, molecular signaling, and diabetes/vascular disease. Her work bridges basic science and clinical applications, aiming to develop novel therapies for metabolic syndrome-related vascular complications.
Professor Guy Williams is a leading academic at the University of Cambridge with a focus on imaging science and clinical neurosciences, affiliated with Downing College and the Wolfson Brain Imaging Centre . Holding a PhD in Physics from his initial Natural Sciences degree, he specializes in nuclear magnetic resonance (NMR) and MRI techniques for brain imaging. Education: BA, PhD in Physics His research centers on non-invasive imaging of brain structure and function, particularly in traumatic brain injury (TBI) and dementia. His work involves developing novel MRI pulse sequences and advanced data analysis algorithms, including AI-based diagnostic tools. He leads studies on white matter integrity post-trauma, longitudinal dementia assessment, and applications of MRI in disorders of consciousness and addiction. Recent publications highlight collaborations in traumatic brain injury outcomes, AI-guided dementia prediction, and neuroimaging of post-COVID cognitive deficits. His team's work on ultra-high field laminar fMRI and distortion correction methods has advanced clinical neuroscience applications. Key techniques include diffusion tensor imaging (DTI), 7 Tesla MRI, and positron emission tomography (PET/MR). His research spans from basic NMR physics to clinical translation, with a strong emphasis on multi-site studies and real-world diagnostic implementation.
